South Dakota Equity Partners

Founded in 2014, Property Meld is a property management maintenance solution that streamlines and automates the maintenance process. Its SaaS platform enables managers, residents, and vendors to schedule, track, and communicate on maintenance requests, enhancing efficiency and tenant satisfaction.

Query provides a federated search platform that helps security teams gain complete visibility into security-relevant data. It enables searching across cloud, third-party SaaS, and on-premises sources in one place without requiring centralization, delivering visual context and detailed answers to security questions. The solution runs directly in the analyst’s browser, offering real-time access and centralized insights while avoiding data duplication from native locations. By simplifying security investigations across disparate platforms, it supports faster, more efficient workflows and can help reduce investigation costs.

Query provides a federated search platform that helps security teams gain complete visibility into security-relevant data. It enables searching across cloud, third-party SaaS, and on-premises sources in one place without requiring centralization, delivering visual context and detailed answers to security questions. The solution runs directly in the analyst’s browser, offering real-time access and centralized insights while avoiding data duplication from native locations. By simplifying security investigations across disparate platforms, it supports faster, more efficient workflows and can help reduce investigation costs.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Nanopareil, LLC is a company specializing in the production of advanced separation modules made from functionalized nanofibers. Founded in 2011 and headquartered in Dakota Dunes, South Dakota, Nanopareil focuses on providing innovative separation media that enhances efficiency in various industries, including biopharmaceuticals, biofuels, and water purification. The company's products utilize a unique mat of electrospun nanofibers, which enable both size-based and adsorptive separation mechanisms. This proprietary technology aims to improve process efficiencies, reduce waste, and simplify manufacturing, making it particularly beneficial for biomedical researchers and manufacturers. In July 2015, Nanopareil changed its name from Nanofiber Separations, LLC and currently operates as a subsidiary of ProMetic BioSciences Ltd.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).